HRP20191683T1 - Liofilizirani liposomi - Google Patents

Liofilizirani liposomi Download PDF

Info

Publication number
HRP20191683T1
HRP20191683T1 HRP20191683T HRP20191683T1 HR P20191683 T1 HRP20191683 T1 HR P20191683T1 HR P20191683 T HRP20191683 T HR P20191683T HR P20191683 T1 HRP20191683 T1 HR P20191683T1
Authority
HR
Croatia
Prior art keywords
liposomes
composition according
composition
agents
mol
Prior art date
Application number
Other languages
English (en)
Croatian (hr)
Inventor
Donna Cabral-Lilly
Lawrence Mayer
Paul Tardi
David Watkins
Yi Zeng
Original Assignee
Jazz Pharmaceuticals Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48141268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20191683(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jazz Pharmaceuticals Res Llc filed Critical Jazz Pharmaceuticals Res Llc
Publication of HRP20191683T1 publication Critical patent/HRP20191683T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
HRP20191683 2011-10-21 2012-10-15 Liofilizirani liposomi HRP20191683T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161550047P 2011-10-21 2011-10-21
EP12841616.1A EP2768484B1 (en) 2011-10-21 2012-10-15 Lyophilized liposomes
PCT/US2012/060293 WO2013059133A1 (en) 2011-10-21 2012-10-15 Lyophilized liposomes

Publications (1)

Publication Number Publication Date
HRP20191683T1 true HRP20191683T1 (hr) 2019-12-13

Family

ID=48141268

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191683 HRP20191683T1 (hr) 2011-10-21 2012-10-15 Liofilizirani liposomi

Country Status (22)

Country Link
US (5) US10028912B2 (https=)
EP (2) EP3572071A1 (https=)
JP (6) JP6133308B2 (https=)
KR (5) KR102452305B1 (https=)
CN (2) CN108853031A (https=)
AU (1) AU2012326370C9 (https=)
BR (1) BR112014009305B1 (https=)
CA (1) CA2852777C (https=)
DK (1) DK2768484T3 (https=)
ES (1) ES2750368T3 (https=)
FR (1) FR19C1063I2 (https=)
HR (1) HRP20191683T1 (https=)
HU (2) HUE045978T2 (https=)
IL (1) IL232161B (https=)
LU (1) LUC00135I2 (https=)
NL (1) NL301016I2 (https=)
NO (1) NO2019041I1 (https=)
PL (1) PL2768484T3 (https=)
PT (1) PT2768484T (https=)
RU (1) RU2648753C2 (https=)
SI (1) SI2768484T1 (https=)
WO (1) WO2013059133A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2768484T1 (sl) * 2011-10-21 2019-12-31 Jazz Pharmaceuticals Research Llc Liofilizirani liposomi
KR20160042079A (ko) 2013-08-13 2016-04-18 노쓰웨스턴유니버시티 펩티드-접합된 입자
US11504322B2 (en) 2014-08-28 2022-11-22 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
CA2958768C (en) 2014-08-28 2023-08-29 The General Hospital Corporation Injectable slurries and methods of manufacturing and using the same
US11471401B2 (en) 2014-08-28 2022-10-18 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
US11298318B2 (en) * 2015-04-13 2022-04-12 Fountain Technologies International, Llc One-step method for production of ultra-small lipid structures
HUE053990T2 (hu) 2015-07-22 2021-08-30 Nitto Denko Corp Nanorészecske liofilizált formák készítményei és eljárások
US10927418B2 (en) * 2015-11-11 2021-02-23 Celator Pharmaceuticals, Inc. Assays and methods for selecting a treatment regimen for a subject with leukemia
US11564830B2 (en) 2016-02-26 2023-01-31 The General Hospital Corporation Medical ice slurry production and delivery systems and methods
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2019010560A1 (en) * 2017-07-10 2019-01-17 Immmunovaccine Technologies Inc. PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION USING LIPID VESICLE PARTICLES OF A DEFINED SIZE, AND USES THEREOF
CN113164502A (zh) 2018-09-25 2021-07-23 塞拉特药物股份有限公司 血液病的低强度治疗
EP3930702A1 (en) 2019-03-01 2022-01-05 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
BR112021026480A2 (pt) * 2019-06-28 2022-02-08 Univ Texas Método para reconstituir anamicina, método para preparar uma dose eficaz de uma formulação lipossômica reconstituída de anamicina e método para tratar câncer
JP2022542571A (ja) * 2019-07-24 2022-10-05 ザ ジェネラル ホスピタル コーポレイション カプセル化により異なる凝固点を有する物質を作製する方法
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN115252563B (zh) * 2022-06-24 2024-07-12 石药集团中奇制药技术（石家庄）有限公司 一种柔红霉素阿糖胞苷脂质体冻干品的制备方法
CN116003493B (zh) * 2022-12-16 2025-02-28 常州金远药业制造有限公司 一种二价铜离子及阿糖胞苷的回收方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
WO1986003938A1 (en) 1985-01-11 1986-07-17 The Regents Of The University Of California Method for preserving liposomes
CA1256372A (en) 1985-04-11 1989-06-27 Koichiro Miyazima Process for producing liposome composition
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US4915951A (en) 1987-12-03 1990-04-10 California Institute Of Technology Cryoprotective reagent
DE68916439T2 (de) * 1988-10-05 1994-10-20 Vestar Inc Verfahren zur herstellung von liposomen mit verbesserter stabilität während des trocknens.
US5049392A (en) * 1989-01-18 1991-09-17 The Liposome Company, Inc. Osmotically dependent vesicles
NZ331372A (en) 1996-02-19 2000-01-28 Nycomed Imaging As freeze-dried vesicle containing a thermally stabilized ultrasound contrast agent
IT1289938B1 (it) 1997-02-20 1998-10-19 Angelini Ricerche Spa Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e
GB9813100D0 (en) 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
HUP0202475A3 (en) 1999-07-16 2004-06-28 Alza Corp A liposome composition having resistance to freeze/thaw damage
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
AU2002331481B2 (en) 2001-10-03 2008-04-24 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
AU2002340670A1 (en) 2001-11-13 2003-05-26 Celator Technologies, Inc. Lipid carrier compositions and methods for improved drug retention
ES2387886T3 (es) * 2001-11-13 2012-10-03 Celator Pharmaceuticals, Inc. Composiciones que transportan lípidos con una mejor estabilidad sanguínea
EP1585504A4 (en) * 2002-11-06 2009-07-15 Azaya Therapeutics Inc Protein stabilized liposomal formulations of pharmaceutical active ingredients
US20040265368A1 (en) * 2003-04-02 2004-12-30 Lawrence Mayer Combination compositions of camptothecins and fluoropyrimidines
EP2407169A1 (en) 2004-04-22 2012-01-18 Celator Pharmaceuticals, Inc. Combination formulations of anthracycline agents and cytidine analogs
US7893338B2 (en) * 2004-07-15 2011-02-22 Creative Technology Ltd Method of composing music on a handheld device
WO2006050327A2 (en) * 2004-10-28 2006-05-11 Alza Corporation Lyophilized liposome formulations and method
US20090285878A1 (en) * 2004-11-05 2009-11-19 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal drug formulations
WO2006055903A1 (en) 2004-11-18 2006-05-26 Celator Pharmaceuticals, Inc. Method for loading multiple agents into delivery vehicles
EP1951239A2 (en) 2005-10-25 2008-08-06 Celator Pharmaceuticals, Inc. Fixed ratio drug combination treatments for solid tumors
WO2007076117A2 (en) 2005-12-22 2007-07-05 Celator Pharmaceuticals, Inc. Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof
PL3300601T3 (pl) * 2007-02-16 2022-05-02 Rotalec Ip Holdings Llc Ustalone stosunki leków do leczenia nowotworów hematopoetycznych i zaburzeń proliferacyjnych
EP2187869B1 (en) 2007-08-17 2015-10-14 Celator Pharmaceuticals, Inc. Improved platinum drug formulations
EP2222278B1 (en) 2007-11-28 2015-04-08 Celator Pharmaceuticals, Inc. Improved taxane delivery system
ES2704986T3 (es) 2008-10-16 2019-03-21 Celator Pharmaceuticals Inc Combinaciones de una camptotecina liposomal soluble en agua con cetuximab o bevacizumab
WO2011066684A1 (zh) 2009-12-03 2011-06-09 江苏恒瑞医药股份有限公司 伊立替康或盐酸伊立替康脂质体及其制备方法
EP2531175A2 (en) * 2010-02-01 2012-12-12 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Liposomes comprising amphipathic drugs and method for their preparation
SI2768484T1 (sl) * 2011-10-21 2019-12-31 Jazz Pharmaceuticals Research Llc Liofilizirani liposomi

Also Published As

Publication number Publication date
CN108853031A (zh) 2018-11-23
US20140255475A1 (en) 2014-09-11
JP2017160211A (ja) 2017-09-14
JP2018150342A (ja) 2018-09-27
EP2768484B1 (en) 2019-07-24
JP6592556B2 (ja) 2019-10-16
JP6359717B2 (ja) 2018-07-18
US10028912B2 (en) 2018-07-24
JP7476161B2 (ja) 2024-04-30
KR102284689B1 (ko) 2021-08-02
BR112014009305A2 (pt) 2017-04-11
RU2014120475A (ru) 2015-11-27
JP6133308B2 (ja) 2017-05-24
KR20220141906A (ko) 2022-10-20
EP2768484A4 (en) 2015-04-22
CA2852777C (en) 2020-10-27
AU2012326370C9 (en) 2023-05-18
HUE045978T2 (hu) 2020-01-28
KR20190111139A (ko) 2019-10-01
NL301016I1 (nl) 2019-10-30
JP2022033892A (ja) 2022-03-02
AU2012326370A2 (en) 2014-06-12
KR20140092323A (ko) 2014-07-23
RU2018107407A3 (https=) 2021-05-04
FR19C1063I1 (fr) 2019-11-22
IL232161A0 (en) 2014-05-28
RU2018107407A (ru) 2019-02-25
AU2012326370C1 (en) 2023-03-30
DK2768484T3 (da) 2019-10-07
US10166184B2 (en) 2019-01-01
LUC00135I2 (https=) 2021-02-12
KR102113753B1 (ko) 2020-05-21
JP2020007367A (ja) 2020-01-16
LUC00135I1 (https=) 2019-10-25
KR102452305B1 (ko) 2022-10-07
AU2012326370A1 (en) 2014-06-05
PT2768484T (pt) 2019-10-28
EP3572071A1 (en) 2019-11-27
KR20200057104A (ko) 2020-05-25
NO2019041I1 (no) 2019-11-25
BR112014009305B1 (pt) 2023-01-24
HUS1900047I1 (hu) 2019-11-28
FR19C1063I2 (fr) 2020-10-30
IL232161B (en) 2019-07-31
CA2852777A1 (en) 2013-04-25
EP2768484A1 (en) 2014-08-27
US10835492B2 (en) 2020-11-17
KR20210095746A (ko) 2021-08-02
RU2648753C2 (ru) 2018-03-28
WO2013059133A1 (en) 2013-04-25
CN104114156A (zh) 2014-10-22
KR102024836B1 (ko) 2019-09-24
US20180161273A1 (en) 2018-06-14
AU2012326370B2 (en) 2017-06-01
US20210169803A1 (en) 2021-06-10
ES2750368T3 (es) 2020-03-25
NL301016I2 (nl) 2020-04-16
US20190070112A1 (en) 2019-03-07
US20230172855A1 (en) 2023-06-08
JP2014532623A (ja) 2014-12-08
PL2768484T3 (pl) 2019-12-31
SI2768484T1 (sl) 2019-12-31
HK1201039A1 (en) 2015-08-21
JP2024045183A (ja) 2024-04-02

Similar Documents

Publication Publication Date Title
HRP20191683T1 (hr) Liofilizirani liposomi
JP2014532623A5 (https=)
JP2024045183A5 (https=)
JP2020007367A5 (https=)
MX2009007089A (es) Preparacion farmaceutica liposomal y metodo para su elaboracion.
JP2001517705A5 (https=)
PT1443900E (pt) Composições de veículo lipídico com estabilidade melhorada no sangue
JP2010519224A5 (https=)
CA2906149C (en) Controlled drug release liposome composition
AR021074A1 (es) COMPOSICIoN FARMACÉUTICA DE MOXIFLOXACINA, PROCEDIMIENTO PARA SU PRODUCCIoN, Y USO DE DICHA COMPOSICIoN PARA PREPARAR UN MEDICAMENTO ANTIBACTERIANO.
BR112012003283A2 (pt) sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente.
JP2019500318A (ja) 細菌感染症を治療するための組成物及び方法
CL2011003046A1 (es) Composicion farmaceutica que comprende 7-(2,5-dihidro-4-imidazo[1,2-a]-piridin-3-il-2,5-dioxo-1h-pirrol-3-il)-9-fluoro-1,2,3,4-tetrahidro-2-(1-piperidinil-carbonil)pirrolo[3,2,1-jk] [1,4]benzodiazepina, una sal o solvato, sbe7-b-cd y opcionalmente un tampon; proceso de preparacion; util para tratar cancer (div. sol. 1848-08).
WO2014003183A1 (ja) パック基材、パック化粧料ならびにパック化粧料キット
EP4103770A1 (en) Patch product based on natural polymers
FI3811931T3 (fi) Liposomikoostumukseen kapseloidun lääkkeen ja immuunitarkistuspisteinhibiittorin sisältävä yhdistelmälääkitys
AR079375A1 (es) Soluciones de rehidratacion oral que comprenden dextrosa. metodo de preparacion.
CN103989624A (zh) 一种盐酸伊立替康组合物及其制备方法
CN102940616A (zh) 一种盐酸氨溴索口腔分散膜剂
CN102935078A (zh) 一种布洛芬口腔分散膜剂
CN102716089A (zh) 一种盐酸吉西他滨脂质体注射剂
JP5429710B2 (ja) 治療薬剤の標的部位への集積及び放出を追跡可能な治療薬剤含有リポソームおよびその製造方法
RU2015117412A (ru) Улучшенный способ получения инкапсулированного в липосомы винкристина для терапевтического применения
CN204659079U (zh) 药用包装铝箔
MX2010008285A (es) Forma galenica para la administracion de triptanos por via trans-mucosa bucal.